Skip to main content
OpenTrials
Completed

NCT Number: NCT05304819

PMCF Study of the AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair

This is a Post Market Clinical Follow Up Study in Orthopaedics, it will verify the long-term safety and performance of the device in the intended patient population, when indicated for the acute repair of the Achilles tendon.

The Medical Device in this study AchilloCordPLUS is a Class IIb UKCA-Marked device manufactured by Xiros Ltd.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

North Cumbria Integrated Care Nhs Foundation Trust

Penrith, CA11 7BF, United Kingdom

About this study

This is a Post Market Clinical Follow Up Study in Orthopaedics, it will verify the long-term safety and performance of the device in the intended patient population, when indicated for the acute repair of the Achilles tendon.

The Medical Device in this study AchilloCordPLUS is a Class IIb UKCA-Marked device manufactured by Xiros Ltd.

AchilloCordPLUS is a single-use device, indicated for patients with acute Achilles tendon ruptures. It is particularly suited to active patients where an extended period of postoperative immobilisation is undesirable.

This study is a prospective, single-centre, consecutively recruited non-randomised study. The total length of the study is expected to be 3 years. This includes a recruitment period of approximately 12 months and a 2-year follow-up.

This study has now closed to follow-up, with a recruitment of 19 participants. Follow up is at 2,4,6,8 and 12 weeks, 6 months and 1 and 2 years. All subjects treated with the AchilloCordPLUS for acute Achilles tendon repair will be consecutively recruited into the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must be skeletally mature and be 18 years old or above.
  • Patients requiring end to end repair for acute Achilles tendon rupture.
  • Patient is willing to participate in the study and have been informed of the nature of the study, agree to its follow-up and has provided written informed consent as approved by the Research Ethics Committee (REC).

Exclusion criteria

  • Patients with chronic ruptures of the Achilles tendon.
  • Patients with bilateral ruptures.
  • Patients with known hypersensitivity to implant materials. Appropriate tests should be carried out on patients with suspected material sensitivity prior to implantation.
  • Patients with infections or any structural or pathological condition of the bone or soft tissue that would be expected to impair healing or prevent secure fixation.
  • Patients who are unable or unwilling to restrict activities to prescribed levels or to follow the rehabilitation instructions during the healing period.

Treatment and study plan

AchilloCordPLUS™ System Implant

Device

AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair

Primary outcomes

  1. Achilles Tendon Rupture Score (ATRS)

    Time frame: 6 months

    Change in ATRS Score 0-100 0=major limitations 100=no limitations

  2. adverse events (AE)

    Time frame: 6 months

    Number of adverse events (AE) at 6 months after surgery which directly relate to the procedure that may have an effect on the patient's outcome (for example, irritation at the surgery site, re-rupture, deep-vein thrombosis (DVT), wound infection and sural nerve damage).

Secondary outcomes

  1. Achilles Tendon Rupture Score (ATRS)

    Time frame: 2 years

    Change ATRS Score from baseline upto 2 years in 0-100 0=major limitations 100=no limitations

  2. Length of time to unaided full weight bearing

    Time frame: 2 years

    Length of time to defined as removal of heel raise and walking unaided

  3. return to work and return to sport.

    Time frame: 2 years

    Time for patients to return to work and return to sport.

  4. Tegner Activity Scale (pre-injury)

    Time frame: 2 years

    Number of patients who have returned to pre-injury levels of activity assessed using the Tegner Activity Scale 10 (competitive sport) 0 (sick leave or disability pension)

  5. RAND Short Form 36 (SF 36) V1

    Time frame: 2 years

    Change from RAND SF 36 Patient-reported quality of life 0-100 a higher sore indicates a higher health state

  6. Tegner Activity Scale (baseline)

    Time frame: 2 years

    Change from Tegner score from baseline to 2 years 10 (competitive sport) 0 (sick leave or disability pension)

  7. Range of Motion

    Time frame: 6 months

    Change in ROM (ankle dorsi and plantar flexion) between each time point up to 6 months after surgery and compare to the contralateral side.

  8. Calf Circumference

    Time frame: 6 months

    Change in calf circumference from 6 weeks up to 6 months and compare to the contralateral side.

  9. Adverse Event

    Time frame: 2 years

    Adverse events up to 2 years after surgery which directly relate to the procedure that may have an effect on the patient's outcome (for example, irritation at the surgery site, rerupture, DVT, wound infection and sural nerve damage).

Sponsors and collaborators

Lead sponsor

Xiros Ltd

Industry

Registry information

Official study title

Post-market Clinical Follow-up (PMCF) Study of the AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Mar 31, 2022
Registry last updated
Apr 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.